Page 3 - ப்ரைமரீ பகுப்பாய்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரைமரீ பகுப்பாய்வு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரைமரீ பகுப்பாய்வு Today - Breaking & Trending Today

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

Share this article
Share this article
RARITAN, N.J., May 19, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA
® plus venetoclax were alive and progression-free at two years.
1 Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).
1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data reinforce the long-term survival benefits and well-established safety profile of single-agent IMBRUVICA ....

United States , Craig Tendler , Jennifer Mcintyre , Paolo Ghia , Christopher Delorefice , Bernadette King , Christie Corbett , None Of The Janssen Pharmaceutical Companies , Global Medical Affairs , Janssen Biotech Inc , American Society Of Clinical Oncology , Drug Administration , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , American Society Of Hematology , American Society Of Clinical Oncology Annual Meeting , Companies Of Johnson , Clinical Development , Clinical Oncology , Annual Meeting , Fixed Duration Cohort , Based Combination Regimen , Previously Untreated , Confidence Interval ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

NOVARTIS AG CHF0.50(REGD)
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy
177
Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
New Kisqali (ribociclib) overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Susanne Schaffert , Fiona Phillips , American Society Of Clinical Oncology , Novartis Institutes For Biomedical Research , Astex Pharmaceuticals , European Hematology Association , Novartis Strategy Financial Communications , Novartis Oncology Communications , Novartis Us External Communications , Exchange Commission , Virtual Congress , Incyte Corporation , Clinical Oncology , Annual Meeting , Hematology Association , Disease Control , With Hormone Receptor Positive , Altered Advanced Breast Cancer , Treated With Alpelisib , Adult Patients ,

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Craig Tendler , Noah Reymond , Jennifer Mcintyre , Paolo Ghia , Christopher Delorefice , Edmond Chan , Global Medical Affairs , Janssen Biotech Inc , American Society Of Clinical Oncology , European Hematology Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , American Society Of Clinical Oncology Annual Meeting , Janssen Cilag Ltd , American Cancer Society , Clinical Development , None Of The Janssen Pharmaceutical Companies , European Commission , Exchange Commission , Companies Of Johnson , Clinical Oncology , Annual Meeting , Area Lead Haematology ,

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Susanne Schaffert , Fiona Phillips , American Society Of Clinical Oncology , Novartis Institutes For Biomedical Research , Astex Pharmaceuticals , European Hematology Association , Novartis Strategy Financial Communications , Novartis Oncology Communications , Novartis Us External Communications , Exchange Commission , Novartis Pharmaceuticals Corporation , Virtual Congress , Incyte Corporation , Clinical Oncology , Annual Meeting , Hematology Association , Disease Control , With Hormone Receptor Positive , Altered Advanced Breast Cancer , Treated With Alpelisib ,

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Craig Tendler , Jennifer Mcintyre , Paolo Ghia , Christopher Delorefice , Bernadette King , Christie Corbett , None Of The Janssen Pharmaceutical Companies , Global Medical Affairs , Janssen Biotech Inc , American Society Of Clinical Oncology , Drug Administration , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , American Society Of Hematology , American Society Of Clinical Oncology Annual Meeting , Companies Of Johnson , Clinical Development , Clinical Oncology , Annual Meeting , Fixed Duration Cohort , Based Combination Regimen , Previously Untreated , Confidence Interval ,